Nark Ted C

SEC Form 4 insider trading activity

Nark Ted C has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: May 8, 2026.

On the most recent filing, Nark Ted C is listed as Director at Amneal Pharmaceuticals, Inc. Inside the rolling window, Nark Ted C reported no open-market purchases and 1 open-market sale totaling $586K in AMRX.

Companies traded

Other insiders at AMRX

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$586K

reported sales (SEC code S)

Companies

1

in the rolling window

Source
AMRX
Nark Ted C
Sale$586KNov 19SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Nark Ted C made?

Nark Ted C has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2025.

Which companies does Nark Ted C trade?

Nark Ted C has filed SEC Form 4 disclosures for 1 company, including AMRX.

When was Nark Ted C's most recent SEC Form 4 filing?

Nark Ted C's most recent SEC Form 4 filing on Tracefour is dated May 8, 2026.

What is Nark Ted C's total buy and sell value in the current window?

Inside the rolling retention window, Nark Ted C bought $0 and sold $586K based on SEC Form 4 filings.

What was Nark Ted C's largest disclosed transaction?

The largest disclosed transaction in the current window is a sale of 50,000 AMRX shares on 2025-11-17, worth $586K, per SEC Form 4 filings.